Critically evaluate the administrative challenges in enforcing pharmaceutical retail regulations across India's federal structure.

Drug regulation in India is a shared responsibility: the Centre frames the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, but licensing and inspection of chemist shops rest with state drug controllers. This split makes the rulebook strong on paper and uneven on the ground.

Strengths of the existing framework

• Uniform central standards: Schedule H and X drugs are sold only against a Registered Medical Practitioner's prescription, and Schedule H1 mandates a separate sale register — prescriber, patient, drug, quantity — kept for three years and open to inspection [1].
• Adaptive rule-making: scheduling can be tightened quickly by notification, as in the July 2026 shift of high-alcohol formulations (>12% v/v, >30 mL) from Schedule K exemption into Schedule H1 [2]. A September 2026 draft proposing CCTV surveillance at retail outlets continues this trajectory.
• Joint enforcement models exist: CDSCO and State Drugs Controllers have run risk-based inspections of over 960 premises since December 2022, yielding 860-plus actions [3].

Administrative challenges

• Capacity deficit: the Mashelkar Committee (2003) flagged weaknesses in the drug regulatory system; PRS notes that neither the 2005 nor 2007 Amendment Bills addressed strengthening regulation at the state level [4]. A central notification cannot create a state inspector.
• Uneven enforcement: identical rules produce different outcomes across states, encouraging inter-state diversion of restricted drugs.
• Weak verification: registers and camera footage are useful only if an inspector demands and cross-checks them; retention, access to sensitive patient data, and installation costs for small rural chemists remain unsettled.
• Partial reach: these are sale-side rules. Overuse and misuse of antimicrobials in humans, animals and agriculture [5] — including prescriber behaviour governed by the National Medical Commission — lies beyond them.

India's problem is not a thin rulebook but thin enforcement machinery beneath it. Strengthening state drug control cadres, digitising prescription-linked sale records, and phasing compliance to local prescriber availability would convert paper safeguards into real ones — advancing both Article 47's public health mandate and SDG-3.